Illumina, Inc.
Every calculator, already run for ILMN
Open the full toolkit →You have the numbers on ILMN. Get the argument.
A written report on which of these readings actually decide the outcome for Illumina, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
21 analysts covering ILMNAnalyst Price Target Disagreement for Illumina, Inc.
Wall Street's bull case implies +8% from the current price; the bear case implies -53%. A 61% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ILMN
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic inst…
ILMN — frequently asked
Is ILMN a buy right now?
Wall Street's consensus rating on Illumina, Inc. is Buy across 21 analysts, with a mean price target of $202.65 (-16% vs. the current $241.66). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ILMN overvalued?
ILMN trades at 45.0x trailing earnings, against a DCF fair value of $80 per share. The current price implies 21% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ILMN's next earnings date?
Illumina, Inc. is next scheduled to report earnings around Oct 29, 2026. A full ILMN research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Illumina, Inc.?
Analysts covering Illumina, Inc. (ILMN) range from a bear-case target of $113.00 to a bull-case high of $260.00, with a mean consensus target of $202.65 across 20 analysts. The spread of $147.00 (61% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Illumina, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Illumina, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ILMN research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Illumina, Inc., in minutes. 3 free reports included with every account — no credit card required.